- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07869147
Study of ORJ-001 for the Treatment of IPF
A Phase 2a/2b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Tolerability (Part A), and Efficacy (Part B), of ORJ-001 in Patients With Idiopathic Pulmonary Fibrosis (ORBIT-IPF)
ORJ-001 is a new class of drugs intended for the treatment of patients with idiopathic pulmonary fibrosis (IPF). This is a Phase 2 study in two parts; the objective of Part A will determine if ORJ-001 is well-tolerated by patients and how long the drug stays in the body. Part B will test how well the drug affects lung function. Animal models of IPF have shown that ORJ-001 can repair damaged lung tissue and improve markers of lung function.
연구 개요
상세 설명
This Phase 2a/2b, randomized, double-blind, placebo-controlled, multicenter study will evaluate the safety, tolerability, and efficacy of ORJ-001 administered subcutaneously twice weekly in adults with IPF. The study consists of two parts. Part A will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of two dose levels of ORJ-001 compared with placebo over 12 weeks of treatment. Data from Part A will be reviewed by an independent Data Monitoring Committee to select the dose for Part B. Participants in Part A will not continue into Part B; Part B will enroll a separate cohort of participants. Part B will evaluate the efficacy of the selected ORJ-001 dose compared with placebo, with the primary efficacy endpoint being change from baseline in forced vital capacity (FVC) at Week 12. Secondary and exploratory assessments include percent predicted FVC, time to acute IPF exacerbation, respiratory hospitalization or death, patient-reported outcomes, pharmacokinetics, and biomarkers of fibrosis. Adults aged 40 years or older with confirmed IPF and adequate pulmonary function who are receiving stable antifibrotic standard-of-care therapy, or who have previously discontinued such therapy due to tolerability or lack of response, may be eligible to participate.
연구 유형
등록 (추정된)
단계
- 2 단계
연락처 및 위치
연구 연락처
- 이름: Clinical Trials
- 전화번호: 1 (832) 400-6140
- 이메일: clinicaltrials@oorjabio.com
연구 연락처 백업
- 이름: Clinical Trials
- 이메일: clinicaltrials@oorjabio.com
연구 장소
-
-
Alabama
-
Birmingham, Alabama, 미국, 35294
- 모병
- University of Alabama at Birmingham
-
수석 연구원:
- Tejaswini Kulkarni, MD
-
-
Florida
-
Doral, Florida, 미국, 33172
- 모병
- Innova Pharma Research, LLC
-
-
Pennsylvania
-
DuBois, Pennsylvania, 미국, 15801
- 모병
- Clinical Research Associates of Central PA
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Key Inclusion Criteria:
- Male or female participants aged ≥ 40 years when signing informed consent
- Non-smoker or ex-smoker who has stopped smoking for > 6 months prior to signing informed consent
- Diagnosis of IPF, as defined by 2022 international guidelines and confirmed by centrally adjudicated finding of a definite or probable UIP pattern on HRCT of the chest. The HRCT may be performed at screening or, if available, a historical HRCT obtained within 12 months from screening may be submitted for central review
- FVC of at least 45% of the predicted value and a DLCO, corrected for the hemoglobin level, of at least 25% and no greater than 90% of the predicted value. Note: Each test (FVC and DLCO) may be repeated once after a minimum of 24 hours if the initial result is deemed unreliable by the investigator
- If receiving SOC antifibrotic therapy, participants must be on a stable regimen of a single approved therapy for at least 60 days prior to the screening visit. Participants who have discontinued SOC antifibrotic therapy due to tolerability or lack of response may be enrolled after at least 30 days of discontinuing the SOC antifibrotic therapy.
- Negative serum pregnancy test in women of childbearing potential at the screening visit
Key Exclusion Criteria:
- Participants who are treatment-naïve with respect to SOC antifibrotic therapies
- Women who are pregnant, nursing, or who plan to become pregnant while in the trial
- Major surgery (including joint surgery) within 8 weeks from screening, or planned major surgery within 4 months following randomization
- Presence of one or more significant concurrent medical conditions that may affect the outcome of the study per investigator judgement
- Participants with relevant airway obstruction, defined as pre bronchodilator forced expiratory volume in 1 second (FEV1)/ forced vital capacity (FVC) ratio < 0.7 at screening
- Lower respiratory tract infection requiring antibiotics within 4 weeks from screening, or during the screening period (may be rescreened following recovery)
- Acute IPF exacerbation within 3 months from screening, or during the screening period
- Receiving more than 15 mg per day of prednisone during screening
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Part A: ORJ-001 400 mg
Participants receive ORJ-001 400 mg administered subcutaneously (SC) twice weekly (BIW) for 12 weeks. Randomization ratio: 3:1:1 (400 mg:200 mg:placebo). |
ORJ-001 is a peptide agonist of β1 integrin administered by subcutaneous injection twice weekly. In Part A, dose levels are 200 mg and 400 mg. In Part B, a single dose level selected from Part A will be evaluated. Matching placebo administered by subcutaneous injection twice weekly. |
|
실험적: Part A: ORJ-001 200 mg
Participants receive ORJ-001 200 mg administered subcutaneously (SC) twice weekly (BIW) for 12 weeks. Randomization ratio: 3:1:1 (active:active:placebo). |
ORJ-001 is a peptide agonist of β1 integrin administered by subcutaneous injection twice weekly. In Part A, dose levels are 200 mg and 400 mg. In Part B, a single dose level selected from Part A will be evaluated. Matching placebo administered by subcutaneous injection twice weekly. |
|
위약 비교기: Part A: Placebo
Participants receive matching placebo administered subcutaneously (SC) twice weekly (BIW) for 12 weeks. |
Matching placebo administered by subcutaneous injection twice weekly. |
|
실험적: Part B: ORJ-001 (Selected Dose)
Participants receive the ORJ-001 dose selected based on Part A safety, tolerability, pharmacokinetic, pharmacodynamic, and efficacy data, administered subcutaneously (SC) twice weekly (BIW) for 12 weeks. Participants are randomized 1:1 to ORJ-001 or placebo. |
ORJ-001 is a peptide agonist of β1 integrin administered by subcutaneous injection twice weekly. In Part A, dose levels are 200 mg and 400 mg. In Part B, a single dose level selected from Part A will be evaluated. Matching placebo administered by subcutaneous injection twice weekly. |
|
위약 비교기: Part B: Placebo
Participants receive matching placebo administered subcutaneously (SC) twice weekly (BIW) for 12 weeks. |
Matching placebo administered by subcutaneous injection twice weekly. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Part A: Safety and Tolerability of ORJ-001: Number of Participants with Treatment-Related Adverse Events (TEAEs)
기간: From first dose through Safety Follow-up Visit, up to 12 weeks.
|
Number of participants experiencing at least one treatment-emergent adverse event. |
From first dose through Safety Follow-up Visit, up to 12 weeks.
|
|
Part A: Safety and Tolerability of ORJ-001: Severity of Treatment-Emergent Adverse Events (TEAEs)
기간: From first dose through Safety Follow-up Visit, up to 12 weeks.
|
Severity of treatment-emergent adverse events as graded according to CTCAE v6.0. |
From first dose through Safety Follow-up Visit, up to 12 weeks.
|
|
Part A: Safety and Tolerability of ORJ-001: Change from Baseline in Systolic Blood Pressure
기간: Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.
|
Change from baseline in systolic blood pressure measured in millimeters of mercury (mmHg). |
Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.
|
|
Part A: Safety and Tolerability of ORJ-001: Change from Baseline in Body Temperature
기간: Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.
|
Change from baseline in body temperature measured in degrees Celsius (°C). |
Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.
|
|
Part A: Safety and Tolerability of ORJ-001: Change from Baseline in Heart Rate
기간: Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.
|
Change from baseline in heart rate measured in beats per minute (bpm). |
Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.
|
|
Part A: Safety and Tolerability of ORJ-001: Change from Baseline in Respiratory Rate
기간: Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.
|
Change from baseline in respiratory rate measured in breaths per minute. |
Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.
|
|
Part A: Safety and Tolerability of ORJ-001: Change from Baseline in Oxygen Saturation
기간: Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.
|
Change from baseline in oxygen saturation measured as percentage (% SpO₂). |
Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.
|
|
Part A: Safety and Tolerability of ORJ-001: Change from Baseline in Corrected QT Interval
기간: Baseline, Week 4, Week 12, and Safety Follow-up Visit up to 12 weeks.
|
Change from baseline in corrected QT interval (QTc) measured by electrocardiogram (ECG) in milliseconds (ms). |
Baseline, Week 4, Week 12, and Safety Follow-up Visit up to 12 weeks.
|
|
Part B: Change from Baseline in Forced Vital Capacity (FVC)
기간: Baseline to Week 12
|
Change from baseline in FVC measured by spirometry at Week 12. |
Baseline to Week 12
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Part B: Change From Baseline in Percent Predicted Forced Vital Capacity (FVC%)
기간: Baseline to Week 12.
|
Change from baseline in percentage of predicted FVC measured by spirometry at Week 12. |
Baseline to Week 12.
|
|
Part B: Time to Acute Exacerbation of IPF, Hospitalization for a Respiratory Cause, or Death
기간: Up to Week 12.
|
Time, in days, to first occurrence of acute IPF exacerbation, hospitalization for a respiratory cause, or death. |
Up to Week 12.
|
공동 작업자 및 조사자
스폰서
수사관
- 연구 책임자: Oorja Bio Medical Director, Oorja Bio, Inc.
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .